Nebenwirkungen · Vyxeos liposomal (previously Vyxeos)
Vyxeos liposomal 44 mg/100 mg powder for concentrate for solution for infusion. · Abschnitt 4.8 · PDF-Seite 8
HOS-226183 · Präparat HOS-217540
Within each frequency grouping, adverse reactions are presented in order of decreasing seriousness. For classification of ADRs which occur at Grades 3-5, a comprehensive listing is available from the NCI at NCI CTCAE. Toxicity is graded as mild (Grade 1), moderate (Grade 2), severe (Grade 3), or life-threatening (Grade 4), with specific parameters according to the organ system involved. Death (Grade 5) is used for some of the criteria to denote a fatality. Table 3: ADRs reported in clinical studies in patients treated with Vyxeos liposomal (n=375)
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-08-04T17:00:00Z · SHA-256 8a5fc4b63f824f6b5649d753d23a6d39d1e229d59b397982252b24f3d06163e4 · Passage 2b31dcfb5a9309547d54ded869e5ec7b25a622936adc6f189403aca98e86f8df · Zeichen 967–1520 im Abschnitt